Explore

Trendline Trendline
Agenus Inc Reports Significant Revenue Growth and Profit in Q1 2026

Agenus Inc Reports Significant Revenue Growth and Profit in Q1 2026

Agenus Inc Reports Significant Revenue Growth and Profit in Q1 2026
Trendline Trendline
Curis Reports First Quarter 2026 Financial Results Amid Ongoing Clinical Trials

Curis Reports First Quarter 2026 Financial Results Amid Ongoing Clinical Trials

Curis Reports First Quarter 2026 Financial Results Amid Ongoing Clinical Trials
Trendline Trendline
Turn Therapeutics Reports Q1 2026 Financial Results and Corporate Updates

Turn Therapeutics Reports Q1 2026 Financial Results and Corporate Updates

Turn Therapeutics Reports Q1 2026 Financial Results and Corporate Updates
Trendline Trendline
Lantern Pharma to Announce Q1 2026 Financial Results, Highlighting AI-Driven Oncology Developments

Lantern Pharma to Announce Q1 2026 Financial Results, Highlighting AI-Driven Oncology Developments

Lantern Pharma to Announce Q1 2026 Financial Results, Highlighting AI-Driven Oncology Developments
Trendline Trendline
Enanta Pharmaceuticals Reports Q2 Financial Results and Advances Clinical Programs

Enanta Pharmaceuticals Reports Q2 Financial Results and Advances Clinical Programs

Enanta Pharmaceuticals Reports Q2 Financial Results and Advances Clinical Programs
Trendline Trendline
Omeros Corporation to Announce First Quarter Financial Results and Host Conference Call

Omeros Corporation to Announce First Quarter Financial Results and Host Conference Call

Omeros Corporation to Announce First Quarter Financial Results and Host Conference Call
Trendline Trendline
IMMEDIATE Therapeutics Strengthens Team to Advance Ischemic Therapy IMT-358

IMMEDIATE Therapeutics Strengthens Team to Advance Ischemic Therapy IMT-358

IMMEDIATE Therapeutics Strengthens Team to Advance Ischemic Therapy IMT-358
Trendline Trendline
Immunome Advances Oncology Pipeline with New Drug Application and Clinical Trials

Immunome Advances Oncology Pipeline with New Drug Application and Clinical Trials

Immunome Advances Oncology Pipeline with New Drug Application and Clinical Trials
Trendline Trendline
Coya Therapeutics Reports Financial Results and Advances ALS Treatment

Coya Therapeutics Reports Financial Results and Advances ALS Treatment

Coya Therapeutics Reports Financial Results and Advances ALS Treatment
Trendline Trendline
Enanta Pharmaceuticals Reports Decreased Net Loss Amid Financial Results for Q2 2026

Enanta Pharmaceuticals Reports Decreased Net Loss Amid Financial Results for Q2 2026

Enanta Pharmaceuticals Reports Decreased Net Loss Amid Financial Results for Q2 2026
Trendline Trendline
Coya Therapeutics Receives FDA Fast Track Designation for ALS Treatment COYA 302

Coya Therapeutics Receives FDA Fast Track Designation for ALS Treatment COYA 302

Coya Therapeutics Receives FDA Fast Track Designation for ALS Treatment COYA 302
Trendline Trendline
Enanta Pharmaceuticals Reports Q2 2026 Financial Results Highlighting Revenue Growth and Strategic Developments

Enanta Pharmaceuticals Reports Q2 2026 Financial Results Highlighting Revenue Growth and Strategic Developments

Enanta Pharmaceuticals Reports Q2 2026 Financial Results Highlighting Revenue Growth and Strategic Developments